Data Under Review
Some valuation figures for this stock are being recalibrated. Hidden fields will return after data review.
Reported as ticker: NATCAPSUQ· We're continuously improving data quality. Contact support if this persists.
NATURAL CAPSULES LIMITED
NATCAPSUQ · General/Diversified · NSE
₹155
Current Market Price
Under Review— We don’t have enough data to publish a fair value estimate for NATCAPSUQ yet. Reason: Data Limited.
Updated just now
YieldIQ Score
—
Piotroski F-Score
4/9
Economic Moat
None
Confidence
21%
ROE
0.3%
Debt/Equity
0.45
WACC
11.1%
Market Cap
₹160.50 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
2.7%
Return on capital employed
EV / EBITDA
—
Enterprise multiple
Debt / EBITDA
—
Leverage vs earnings
Interest Coverage
1.4×
EBIT covers interest
Current Ratio
1.30×
Short-term liquidity
Asset Turnover
0.41×
Revenue per ₹ of assets
Revenue CAGR (3Y)
4.4%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
Ratio Trends
NATCAPSUQ · last 4 annual periods
ROE
0.3%
ROCE
2.7%
Operating Margin
—
Debt / Equity
0.45×
PE
—
EV / EBITDA
—
Historical Financials
NATCAPSUQ · Annual, last 4 years· amounts in ₹Cr unless noted
| Metric | 2022 yfinance | 2023 yfinance | 2024 yfinance | 2025 yfinance | CAGR |
|---|---|---|---|---|---|
| Revenue | ₹130 Cr | ₹165 Cr | ₹151 Cr | ₹164 Cr | +8.1% |
| EBITDA | ₹26.4 Cr | ₹35.6 Cr | ₹21.8 Cr | ₹18.2 Cr | -11.6% |
| EBIT | ₹21.3 Cr | ₹28.4 Cr | ₹13.2 Cr | ₹9.1 Cr | -24.7% |
| PAT | ₹13.9 Cr | ₹18.4 Cr | ₹5.6 Cr | ₹0.6 Cr | -64.6% |
| EPS (diluted) | ₹19.84 | ₹19.86 | ₹5.97 | ₹0.63 | -68.4% |
| CFO | ₹-0.5 Cr | ₹17.2 Cr | ₹-8.4 Cr | ₹26.8 Cr | — |
| CapEx | ₹-46.1 Cr | ₹-106 Cr | ₹-71.6 Cr | ₹-44.6 Cr | — |
| FCF | ₹-46.6 Cr | ₹-88.7 Cr | ₹-80.0 Cr | ₹-17.9 Cr | — |
| Total Assets | ₹164 Cr | ₹289 Cr | ₹377 Cr | ₹419 Cr | +36.7% |
| Total Debt | ₹52.8 Cr | ₹96.8 Cr | ₹109 Cr | ₹105 Cr | +25.8% |
| Shareholders' Equity | ₹83.0 Cr | ₹123 Cr | ₹204 Cr | ₹233 Cr | +41.1% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
NATCAPSUQ vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
BROOKS BROOKS | — | — | Pending | -10.2% | — |
ALPA ALPA LABORATORIES LTD | -7.6% | 17 | Near Fair Value | 11.4% | — |
KREBSBIO KREBSBIO | — | — | Pending | 10.4% | — |
AAREYDRUGS AAREYDRUGS | — | — | Pending | 2.9% | — |
BALPHARMA BALPHARMA | — | — | Pending | 9.3% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for NATCAPSUQ in the last 10 years.
Risk Analysis
Volatility & drawdown
Risk profile of NATCAPSUQ →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for NATCAPSUQ →
Compare
Head-to-head with peers
Compare NATCAPSUQ side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse NATCAPSUQNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.